Clinical Trial Update: Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating pembrolizumab in combination with TS-1 plus either cisplatin or oxaliplatin as first-line therapy for gastric cancer; results have been…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• OXALIPLATIN (Oxaliplatin)
• Pembrolizumab (pembrolizumab)
• TS-1 (S-1) (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Gastric Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-12-01